Vaxcyte annual current ratio
2019
2020
2021
2022
2023
2024
2025
Vaxcyte Current Ratio Growth & History (PCVX)
Vaxcyte's current ratio was 7.91 for fiscal 2025.
View full Vaxcyte company overviewVaxcyte annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.91 | −4.85 | −37.99% |
| 2024 | 2024-12-31 | 12.75 | 5.21 | +69.15% |
| 2023 | 2023-12-31 | 7.54 | −15.72 | −67.58% |
| 2022 | 2022-12-31 | 23.26 | 14.33 | +160.54% |
| 2021 | 2021-12-31 | 8.93 | 0.63 | +7.54% |
| 2020 | 2020-12-31 | 8.30 | 2.72 | +48.64% |
| 2019 | 2019-12-31 | 5.58 | — | — |
Vaxcyte quarterly current ratio
Q4.19
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.72 | −5.38 | −48.47% |
| Q1 2026 | 2026-03-31 | 7.49 | −10.21 | −57.67% |
| Q4 2025 | 2025-12-31 | 7.91 | −4.85 | −37.99% |
| Q3 2025 | 2025-09-30 | 8.83 | −9.05 | −50.61% |
| Q2 2025 | 2025-06-30 | 11.11 | −6.78 | −37.89% |
| Q1 2025 | 2025-03-31 | 17.70 | 0.28 | +1.61% |
| Q4 2024 | 2024-12-31 | 12.75 | 5.21 | +69.15% |
| Q3 2024 | 2024-09-30 | 17.88 | 2.74 | +18.12% |
| Q2 2024 | 2024-06-30 | 17.88 | −3.88 | −17.82% |
| Q1 2024 | 2024-03-31 | 17.42 | 1.48 | +9.28% |
| Q4 2023 | 2023-12-31 | 7.54 | −15.72 | −67.58% |
| Q3 2023 | 2023-09-30 | 15.14 | 5.73 | +60.96% |
| Q2 2023 | 2023-06-30 | 21.76 | 9.82 | +82.27% |
| Q1 2023 | 2023-03-31 | 15.94 | 3.38 | +26.90% |
| Q4 2022 | 2022-12-31 | 23.26 | 14.33 | +160.54% |
| Q3 2022 | 2022-09-30 | 9.41 | 3.02 | +47.36% |
| Q2 2022 | 2022-06-30 | 11.94 | 4.53 | +61.16% |
| Q1 2022 | 2022-03-31 | 12.56 | 6.66 | +112.79% |
| Q4 2021 | 2021-12-31 | 8.93 | 0.63 | +7.54% |
| Q3 2021 | 2021-09-30 | 6.38 | −3.74 | −36.92% |
| Q2 2021 | 2021-06-30 | 7.41 | −5.15 | −41.01% |
| Q1 2021 | 2021-03-31 | 5.90 | — | — |
| Q4 2020 | 2020-12-31 | 8.30 | 2.72 | +48.64% |
| Q3 2020 | 2020-09-30 | 10.12 | — | — |
| Q2 2020 | 2020-06-30 | 12.56 | — | — |
| Q4 2019 | 2019-12-31 | 5.58 | — | — |
Vaxcyte current ratio trends
Over the last five fiscal years, Vaxcyte's current ratio decreased from 8.30 to 7.91, a change of −0.39. The latest reported quarter, Q2 2026, shows 5.72.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxcyte source filings ↗